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SUMMARY 
Genetic predisposition is an important contributor in development of human complex 
diseases, like rheumatoid arthritis (RA). In this thesis work, we present advances for 
involvement of non-HLA genetic risk factors for RA. In the same study, by using 
methods of genetic epidemiology and molecular genetics, we demonstrate how even 
moderate contribution from candidate genes could be found, interpreted and how this 
may affect important biological functions. 
The majority of the study has been performed in a large population based cohort of 
Swedish RA patients with matched controls and with additional cohorts from Norway, 
UK and the Netherlands. Data has been generated with both TaqMan allelic 
discrimination and DNA array-based genotyping. A subset of the cohort has been used 
for studying mRNA expression with quantitative PCR. Three risk loci have been 
investigated in this thesis: the MHC class II Transactivator (CIITA), the Dendritic Cell 
Immunoreceptor (DCIR) and Protein Tyrosine Phosphatase Non receptor 22 
(PTPN22). For CIITA we aimed to produce further evidence for association with 
disease by replication and fine mapping of the locus. For DCIR and PTPN22 our aim 
was to examine the gene expression for finding potential regulatory differences.  
We present data that CIITA is a valid risk factor for RA and that this risk seems to be 
population specific. The risk for disease was higher in the subgroup defined by shared 
epitope (SE) positivity. We extensively analyzed a possible interaction effect for the 
risk of developing disease in four independent populations. However, no significant 
interaction between the CIITA and the HLA-DRB1 locus was found. When measuring 
expression of promoter isoforms of CIITA in cells from peripheral blood, we found that 
both CIITA_pIII and CIITA_pIV expression are associated with genetic variation in the 
locus.  
For DCIR we could establish that five splice forms were present in blood mononuclear 
cells, including a novel variant, which were down regulated upon immunostimulation. 
Transcript DCIR_v4 was associated with genetic variation in the locus. This correlation 
was similar for both RA patients and controls. 
Finally, we present a novel finding that the expression of PTPN22 splice forms is 
different for RA patients and healthy controls with more of the full-length, putatively 
more active, splice forms for patients and less of the alternative variant. This mixed 
effect was replicated in three independent cohorts.  
In conclusion, we present a framework for delineating genetic risk association signals 
by fine-mapping loci and combining with expression analysis of existing splice forms. 
More specifically, we give further insights for three genetic risk factors for RA that 
may lead to less expression of HLA class II (CIITA) and stronger inhibition of immune 
cell signaling (DCIR and PTPN22).  
A combined orchestrated effect of all this risk variants together with other risk factors 
known for RA may be what predisposes certain individuals for rheumatoid arthritis. 
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1 INTRODUCTION 
 
This introduction aims at giving the reader a background for the included papers and 
also lift up the importance that research is carried out in this field. It is also aimed at 
giving the proper relevance for the aim of the thesis. It covers a brief overview of the 
disease at topic, rheumatoid arthritis (RA), risk factors for developing disease, the 
means of studying the disease with genetic tools and how this is done in patient cohorts. 
 
1.1 ABOUT RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis is a multifactorial disease with established genetic [1] and 
environmental components [2-5] that has a dramatic effect on life quality and confer 
great costs for the society. This chapter intends to give a broad introduction of what is 
known for the disease etiology and the associated risk factors.  
 
1.1.1 Disease characteristics 
 
On average one percent, depending on population, suffer from RA, which is typically a 
life long diagnosis [6]. The disease is more common for women than men with about a 
3:1 ratio. The prevalence of RA is population dependent: it is more common for 
individuals with European ancestry than Asian [7, 8] with extraordinary high disease 
frequency for some native American populations (5% for Pima and 7% for Chippewa 
populations)[9-11]. RA is classified as an autoimmune disease, meaning that the 
disease, although it may be triggered by something else, is sustained by the individual’s 
own immune system with a clear role of the adaptive immunity. About 3-5% from a 
general population suffer from an autoimmune disease and for most of these there is a 
heritable component [6, 12] Evidence for autoimmunity are antibodies directed at self-
antigens, so-called autoantibodies that may be detected in early RA and sometimes 
even before disease onset [13]. It is also said to be a complex disease where possibly 
multiple genetic risk variants in the genome acts to increase the risk for disease together 
with environmental exposures. The study of these combinatorial effects of risks is even 
further complicated by the fact the disease is diagnosed by several criteria. These are 
described by the American College of Rheumatism 1987 revised criteria for the 
classification of RA, Table 1. [14]  
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Table 1. The 1987 revised criteria for the classification of rheumatoid arthritis (ACR-87). 
Criterion Definition 
1. Morning stiffness Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement 
2. Arthritis of 3 or more 
joint areas 
At least 3 joint areas simultaneously have had soft tissue swelling or 
fluid (not bony overgrowth alone) observed by a physician. The 14 
possible areas are right or left PIP, MCP, wrist, elbow, knee ankle 
and MTP joints 
3. Arthritis of hand joints At least 1 area swollen (as defined above) in a wrist, MCP, or PIP 
joint 
4. Symmetric arthritis Simultaneous involvement of the same joint areas (as defined in 2) on 
both sides of the body (bilateral involvement of PIPs, MCPs, or 
MTPs is acceptable without absolute symmetry) 
5. Rheumatoid nodules Subcutaneous nodules, over bony prominences, or extensor surfaces, 
or in juxtaarticular regions, observed by a physician 
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum rheumatoid factor by 
any method for which the result has been positive in <5% of normal 
control subjects 
7. Radiographic changes Radiographic changes typical of rheumatoid arthritis on 
posteroanterior hand and wrist radiographs, which must include 
erosions or unequivocal bony decalcification localized in or most 
marked adjacent to the involved joints (osteoarthritis changes alone 
do no qualify) 
For classification purposes, a patient shall be said to have rheumatoid arthritis if he/she has satisfied at 
least 4 of these 7 criteria. Criteria 1 through 4 must have been present for at least 6 weeks. Patients with 
2 clinical diagnoses are not excluded. Designation as classic, definite, or probable rheumatoid arthritis 
is not to be made. PIPs = proximal interphalangeal joints, MCPs = metacarpophalangeal joints, MTPs = 
metaarsophalangeal joints. Table modified from Arnett et al., 1988 [14]. 
 
It is important to point out that RA is a systemic disease, involving the immune system 
for mediating effects to sites of inflammation, which is evident from the usual 
symmetry of the affected joints. The cardiovascular and the lymphatic systems are the 
transport systems mediating the major immune responses by circulating cells and 
effector molecules. 
Criteria number 6, presence of rheumatoid factor (RF), is of special interest since it 
clearly divides the patients in two distinct groups. RF describes antibodies against the 
Fc part of IgG giving rise to immune complexes and was first described by Erik Waaler 
in the year 1940[15]. This factor is not specific for RA and is found in several 
autoimmune diseases [16-18] and is also found in normal population. In a follow up of 
RF positive healthy individuals it was found that about a fifth had developed RA [19].  
Recently, autoantibodies targeting citrullinated peptides has been found to be much 
more specific for rheumatoid arthritis than RF where many individuals are seropositive 
for both [20, 21]. These anti-citrullinated peptide antibodies (ACPA) are present in 50-
70% of all RA patients and are found in less than 2% of the normal population [22]. 
ACPA status is usually determined by anti cyclic citrullinated peptide (anti-ccp) 
   3 
ELISAs that use a mix of citrullinated peptides [22]. In 2010 a new classification 
criteria set for RA was presented that included the presence of ACPA as alternative to 
RF [23]. 
 
1.1.2 Autoantibodies, fine specificity 
 
Citrullination, or deamination as it is also called, is a post-translational modification 
with a conversion of the amino acid arginine (R) to citrulline by peptidiylarginine 
deiminases (PADs). This modification alters the charge and possibly structure of the 
protein, giving rise to possible new epitopes foreign for the immune system. 
Citrullinated proteins have been shown to be abundant in the synovial fluid of arthritis 
patients where it is missing in osteoarthritis patients [24]. It seems, however, that not all 
citrullinated proteins trigger antibody production in RA patients. Specifically, four 
proteins have been described this far: fibrinogen, vimentin, collagen type II and alpha-
enolase. Interestingly, the commonly used anti-cyclic citrullinated peptides (anti-ccp) 
assay does not completely overlap positive detection for antibodies towards these 
citrullinated proteins. For instance, about 4-7% of RA patients are positive for 
citrullinated alpha-enolase antibodies but negative for anti-ccp [25].  
 
1.1.3 Cost for society 
 
Due to that RA is a chronic disease that, if left untreated, leads to severe and 
irreversible damage to the cartilage of joints it leads to loss of physical functions and 
ultimately to handicap. This reduced quality of life is not only a major consequence for 
the affected individuals but also a dramatic cost for society. For instance, for the 
Swedish population it was estimated that the increased amount of sick leave due to RA 
amounts to a cost of 215 million euro during the year 2007 [26]. This is for a relatively 
small country and the estimate does not include the cost for care and medicines, which 
has increased with new therapies for autoimmune disease, hence, there is a lot to gain 
by learning more about the disease etiology that can lead to more efficient medication 
and more effective patient diagnosis.  
 
1.1.4 Genetic component 
 
The heritability of RA has been estimated in twin studies of Finnish and British 
population and is around 60% (Heritability 53-65% in UK resp Finnish population) and 
concordance rate for monozygotic twins is reported be 15-21% [1, 27, 28]. This 
establishes that there is a genetic component in the etiology of RA that is partly 
responsible for development of the disease. Before large genomic screens became 
available for RA, there were only a handful of genetic risk factors known with 
variations in the HLA-DRB1 gene being the absolute strongest.  
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HLA-DRB1 
HLA-DRB1 is an antigen presenting protein and the corresponding gene is encoded in 
the major histocompatibility complex (MHC) class II locus. This association to arthritis 
was discovered over 30 years ago [29] and has been replicated numerous times. A more 
detailed relationship was presented in the shared epitope hypothesis by Gregersen et al. 
(1987) that described a set of HLA-DRB1 alleles with a common protein motif to be 
responsible for the increased risk. These alleles were collectively termed the shared 
epitope (SE) because of the shared aminoacid seuquence at position 67-74 which is part 
of the third hypervariable loop, exposed in the binding cleft of HLA-DRB1 [30, 31]. In 
further studies it has become clear that the SE effect was only observed for sero-
positive individuals, and more specifically presence of ACPA and that there is a dose-
response relation [32, 33]. This gives further evidence that the presence of these 
antibodies distinctly divides patients in two subgroups that have, at least partly, 
different disease etiologies and where genetic factors predispose to one or the other.  
Other variants in the HLA-DRB1 locus have been associated with protection or a milder 
form of disease [34-39].  
PTPN22 
Outside the HLA complex, variants in PTPN22 are the most undisputable genetic risk 
factor for developing RA. The first report of association with disease came in 2004 for 
type 1 diabetes (T1D) from a candidate gene study [40]. This was quickly replicated in 
other cohorts and also for other diseases such as RA [41-44], SLE [42, 43, 45] and 
Graves’ disease [46, 47] and in summary it has been associated with more than ten 
autoimmune diseases to date. It is also an incredible reproducible risk factor across 
populations and the associated risk variant exists mainly in individuals with European 
ancestry with the highest reported allele frequency in Finnish population (15.5% in 
controls)[48] and lowest for Italian (2%)[40]. The risk variant is almost absent in 
African individuals (MAF~0.005) and has a low frequency in Asian population (MAF 
0.01-0.02)(www.hapmap.org).  
The variant associated to disease, 620W (rs2046601), confers a substitution of arginine 
(R) to tryptophan (W) in the non-catalytic part of LYP, the protein of PTPN22, where a 
SRC homology 3 (SH3) domain is predicted to be affected.  
It is predicted from mice studies that this domain has a high affinity with c-Src tyrosine 
kinase, CSK [49, 50]. This interaction may affect LYPs ability to dephosphorylate 
lymphocyte-specific protein tyrosine kinase, LCK, which is part of the signal pathway 
of the T cell receptor (TCR). A reduction of affinity in the SH3 domain by the 620W 
mutation may then lead to reduced formation of LYP/CSK complexes with a result in 
altered signaling through TCR [49].  
However, studies in T cell lines and primary human cells have shown that the 620W 
variant is associated with an increase in dephoshporylation of downstream targets that 
would be a gain of phosphatase activity for LYP leading to an attenuation of TCR 
signaling [51], which is further supported by a study showing reduced T cell 
responsiveness to antigen stimulation for individuals homozygous for 620W [52]. 
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Similar studies of B cells from individuals carrying the 620W allele are also pointing at 
an impaired response of the receptor and an overall reduction of phosphorylated key 
signaling proteins, which was reversed on inhibition of LYP [53].  How these findings 
are connected to a mutation not positioned in the active catalytic domain is not clear 
and does not follow the expected effect of altered affinity of the SH3 domain. In 
another experiment with Jurkat cells, co-transfecting 620W with CSK significantly 
increased phosphorylated ERK compared to 620R allele [54]. This would be 
interpreted as a loss of function with an increased TCR signaling as result.  
Thus, it remains to find out what the role of PTPN22, and more specifically the 620W 
allele, has for autoimmune disease.  
Besides these two well-established risk factors for RA, this thesis involves two other 
genes – the MHC class II transactivator (CIITA) and the dendritic cell immune receptor 
(DCIR).  
CIITA 
Initially CIITA was discovered in a locus responsible for expression differences of 
MHC class II molecules between rat strains in a nerve injury trauma model. In a human 
candidate gene approach, it was found that a variation, -A168G (rs3087456), was 
associated with RA, multiple sclerosis (MS) and myocardial infarction. It could also be 
shown that -168G was correlated with a lower expression of CIITA and HLA-DRA 
[55]. The association of CIITA with RA has been replicated with varying results [43, 
56-59] and a meta-analysis in 2008 concluded that there was no overall association 
with RA [60]. The association with MS seems however to replicate in several studies 
[59, 61-63] and association with celiac disease [64], ulcerative colitis [65] and 
Addison’s disease [66] have been reported. 
The biological role of CIITA was discovered when a cell line derived from a patient 
with hereditary MHC class II deficiency (or bare lymphocyte syndrome) was 
complemented with a vector expressing CIITA that restored surface class II antigen 
expression [67]. It was subsequently found that expression of CIITA is required for both 
MHC class II expression and antigen presentation [68]. CIITA is part of the 
transcription complex used by the MHC class II promoters but does not directly bind to 
DNA itself, instead mediating its essential effect through the other transcription factors 
involved. Also, CIITA exhibits cell specific expression that parallels that of HLA class 
II [69, 70] and is regulated by multiple promoters leading to four different promoter 
isoforms, denoted CIITA_p1-p4 [71]. These isoforms are expressed in cell specific 
manner where CIITA_p1 is described as dendritic cell and macrophage specific [71, 
72], CIITA_p2 has been detected in a melanoma cell line [73], CIITA_p3 in monocytes, 
dendritic cells and B cells [74] and CIITA_pIV is mainly inducible by IFN-gamma  in 
many antigen presenting cells [71]. 
This complexity of several promoters of CIITA and the fact that it seems to tightly 
regulate expression of HLA class II suggest that the fine-tuning of antigen presenting 
molecules is of uttermost importance for the balance of immunity and self-tolerance 
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and makes it an attractive target to study given the clear involvement of HLA in 
autoimmune disease. 
DCIR 
Dendritic cell immunoreceptor (DCIR) was mapped in our lab in a quantitative trait 
locus in a congenic rat strain protected from oil-induced arthritis. This locus contained 
several antigen-presenting lectin-like receptor genes and five corresponding genes in 
human were genotyped.  Variants in DCIR were found to be associated with sero-
negative disease with an OR of 1.37 (95% CI 1.12-1.67) [75].  
DCIR is also known as CLEC4A (official HGNC name), LLIR, DDB27, CLECSF6 and 
HDCGC13P. DCIR is a member of the C-type lectin superfamily where the lectin 
domain is associated to functions such cell adhesion, cell signaling and other roles in 
immune response to pathogens and apoptosis [76, 77] with requirement of calcium for 
binding. DCIR also has an ITIM domain, which suggest an inhibitory function. With 
the assistance of Src-kinases, ITIM can interact with SHP-1 and SHP-2, which are 
phosphotyrosine phosphatases with potential to dephosphorylate molecules, which can 
result in a decrease of activating signals [78].   
The number of genes (closest to associated genetic variants) associated to RA is now 
over 30 [79], which gives an insight of the complexity of the genetic background for 
the disease.  
 
1.1.5 Environmental component 
 
The idea the RA is triggered by an environmental exposure has been thoroughly 
studied. The resemblance of the characteristics of borreliosis (Lyme disease), an 
infectious disease caused by bacteria transferred by tics, with chronic rheumatoid 
arthritis gives the idea that bacterial or viral infections may trigger the disease [80]. 
There are reports of antibodies toward citrullinated viral peptides in RA patients that 
may play a role for the disease etiology [81, 82]. One of the hypotheses behind 
infections as a trigger for RA and loss of tolerance to self is molecular mimicry. An 
emerging candidate for this is the Porphyromonas gingivalis bacterium that causes 
periodontitis. It has been shown that periodontitis is more common in RA patients than 
normal populations [83-85] and together with the fact that P. gingivalis is the only 
bacteria known to express the PAD enzyme that converts arginine to citrulline, also 
shown to convert human proteins in vitro, it is an interesting etiology hypothesis [86]. 
The most well-known environmental risk factor that has been repeatedly connected to 
RA is smoking [2-5, 87-90] with a clear dose effect on the risk and the effect exists 
several years after cessation [2, 87, 88]. The exact mechanism behind this is still not 
clear but recent discoveries may hint at the process. Firstly, the risk of disease from 
smoking was greatly increased for individuals carrying the SE alleles in a dose 
dependent manner, i.e. homozygous individuals have the highest risk [33]. Then studies 
of smoking and ACPA revealed that smoking was exclusively a risk for the ACPA 
positive individuals and that this was linked to these specific autoantibodies rather than 
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RF [32]. This together with information about citrullinated proteins in lungs from 
smokers lead to a hypothetical disease etiology presented by Klareskog et al, 2006, 
suggesting that smoking may cause self-reactivity towards citrullinated proteins in a 
certain genetic background (SE) the eventually leads to RA (Figure 1) [32]. The 
question, however, how this targets the focus of the disease - joints, is still to be 
answered. 
APC 
T-cell 
Smoking 
MHC2  
(SE alleles) 
Citrullination 
of peptides 
Anti-CP 
Citrullinated  
peptide 
TCR 
PTPN22 regulates 
T-cell activity 
Activation of  
T-cells 
  MHC2TA regulates 
 MHC2 expression  
RA 
 
Figure 1. The figure illustrates the proposed etiology by Klareskog et al. by combing the different risk 
factors found for RA.  
 
There is also support for other environmental factors that are associated with RA 
patients. Studies have shown that consumption of alcoholic beverages is less frequent 
for individuals developing RA [91, 92] implying a possible immunosuppressing 
function, which is supported by other observations [93]. Silica dust [94-97], mineral oil 
[98] and dietary effects of fruit, red meat and Mediterranean food [99-101] have also 
been associated with RA, but to a less extent. 
 
1.2 GENETICS 
 
The human genome is full of variations. These variations allow for adaption and 
survival under different environmental conditions and are key to the evolutionary 
process. Lately, however, they have become the focus of endemic autoimmune 
diseases, which may be a result of an effective immune system adapted and evolved to 
fight of infections. 
The common variations in the genome consist of: Single nucleotide polymorphism 
(SNP), is a mutation of one base to another; Insertions and deletions (indels) which are 
inserted or lack of nucleotides in the sequence; Copy number variations (CNVs), are 
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stretches of copied sequences ranging from 1000 bases (1kb) up to several megabases 
(Mb)[102, 103]; Microsatellites or short tandem repeats are short repetitive elements of 
about 1-4 bases dispersed mainly in the non-coding part of the genome [104] with an 
exceptionally high mutation rate [105, 106]; other structural variations such as 
inversion, translocation and segmental uniparental disomy [107]. 
With the event of the complete sequence of the human genome we have gained further 
insight of the genetic diversity. The Human Genome Project (HGP) and Celera 
published the first draft of the human genome in 2001[108, 109]. The complete 
sequence (Build 35) was presented by the HGP in 2004 and consisted of 2.85 billion 
nucleotides (109 nt) with an estimate of 20000-25000 protein-coding genes, which 
occupies only about 1.5% of the genome [108, 110]. This landmark in biology has lead 
to many insights about the genome structure. It has showed that even though SNPs 
clearly are in majority of the variant events, other structural variations (CNVs) 
represent the largest genetic variance by involving 74% of all variant nucleotides. On 
average, this work estimates that humans are 99.5% similar in the genome where, 
roughly, SNPs are responsible for 0.1% difference [111]. The increasing number of 
sequenced genomes, however, results in new variants with every individual hinting that 
we still have not understood the full complexity of genetic variability. Also, the 
complexity that the diploid status of the genome should not be forgotten, which results 
in that a human can have either one or two copies of these affected alleles 
(heterozygous or homozygous), which may or may not be active. 
These described differences, forms the key for genetic studies of susceptibility for 
disease. During the recent years, SNPs have become increasingly important for 
conducting large genetic studies due to their distribution and ease of detection. They 
may even be used for inferring or imputing other types of genetic variability. A deeper 
description of these variations is given in the next section. 
 
1.2.1 Single nucleotide polymorphisms 
 
The rapid discoveries of SNPs in the human genome, with the HapMap initiative as one 
of the driving forces [112], have facilitated the performance of large genetic studies. 
Without this foundation none of the GWASs studies would have been possible. Due to 
the fact that SNPs may have a small effect they can be found even in coding parts of the 
genome, though it is less frequent where amino acids are affected and tends to be 
higher at 5’-UTR regions [113]. This dispersion throughout the genome allows for a 
better resolution and coverage when comparing individuals by genotype, which is one 
of the major reasons why it is so commonly used.    
Depending on the position of a SNP, either intergenic, 5’ or 3’ untranslated regions 
(UTRs), intronic or exonic, different properties are expected. Historically, mutations in 
the intergenic region of the genome (the so-called “gene desert”) were considered to 
have very little effect on cell biology but discoveries of novel RNA-genes, epigenetic 
factors affecting histone composition etc., have changed this. This is very likely an 
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underestimated region where further research is warranted. SNPs in exonic regions can 
either be synonymous, meaning that the change of nucleotide does not alter the 
resulting amino acid, or they can be non-synonymous. The latter can further be 
described as missense, when an amino acid is changed or a nonsense mutation leading 
to a premature end of the translation. Non-synonymous mutations are often behind rare 
Mendelian traits due to the big impact they may infer on protein function. Synonymous 
mutations may still affect the protein by changing the translation and splicing 
efficiency. This has been studied on a genome wide basis where it was shown that a 
synonymous SNPs affecting translational efficiency were under negative selection for, 
amongst others, regulatory genes [114]. SNPs in the close vicinity of coding sequence, 
i.e. 5’-UTR, intronic or 3’-UTR, may affect very important regulatory features 
(described in a later section) such as transcriptional regulation by affecting transcription 
factor binding sites (TFBS) activity, changing of splicing pattern or efficiency by 
disrupting splice site, exonic splicing enhancers or silencers. The 3’ UTR is also a 
region of gained interested with discoveries of regulation of protein translation by 
microRNA (miRNA) that often targets mRNA transcripts in this region [115]. An 
estimate of the amount of genes that may be targeted by miRNA varies (30-60%) but 
the mechanism seems to be of importance for a large set of genes [116, 117]. 
 
1.2.2 Genetic linkage 
 
During the meiosis the chromosome pairs are crossed into new combinations, a process 
called homologous recombination. This procedure results in an increased diversity and 
is beneficial for adaption of organisms to environment. The recombination breaks the 
chromosomes at seemingly random positions and then joins the chromosome pair in 
cross over fashion. The amount of recombination, i.e. the recombination frequency, 
between two loci is a measure of genetic linkage and is a rough estimate of their 
distance. The recombination frequency of 1% is termed a centimorgan (cM) and is 
often used for describing distance between two loci. However, certain regions of the 
genome are less recombined then expected by a random procedure, which results in 
that the combination of alleles are inherited intact. This is called linkage disequilibrium 
(LD) and the measure of LD is called D and is calculated according to Figure 2.  
The measure of D is in reality seldom used since it varies with allele frequencies. 
Instead it is often normalized with the theoretical maximum of observed allele 
frequencies [118, 119] or the square root of the product of allele frequencies to receive 
the correlation coefficient r.[120]  
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Haplotype A1-B1, observed frequency f11 
Haplotype A1-B2, observed frequency f12 
Haplotype A2-B1, observed frequency f21 
Haplotype A2-B2, observed frequency f22 
 
D = observed frequency – expected frequency  
D = f11 – (f11+ f12) x (f11 + f21) 
A1 B1 
A2 B2 Locus A Locus B 
 
Figure 2. The box explains the LD measure between loci, A and B, with two alleles each. The measure D 
is calculated from the deviation of observed frequency of a haplotype from the expected in a population 
of individuals [121].  
 
1.2.3 Transcription 
 
The region directly upstream of the coding sequence is denoted the promoter and 
contains DNA motifs essential for the transcription initiation, see Figure 3 for 
schematic representation. The creation of mRNA from genes follows an orchestrated 
sequence of events the ultimately leads to the correct position of the RNA polymerase 
for transcription. The core promoter consists of necessary and well-conserved elements 
for RNA polymerase binding that stretches from about -40bp from the transcription 
initiation site to roughly +30 bp into the coding sequence. A typical promoter consists 
of three elements: the BRE motif that binds TFIIB; the TATA motif that binds TBP and 
the initiator (Inr), which may or may not be present. The most well described element 
of these is the TATA-motif, named after the nucleotides of the motif (TATAAA) 
positioned at ~-30 bp [122]. The TATA-motif is conserved throughout evolution and is 
present in about a third of human promoters [123]. The initiator motif is usually a 
cytosine at the −1 position and adenosine at the transcription start site and pyrimidines 
around these nucleotides [124]. These elements determine the direction and efficiency 
of the transcription of RNA polymerase II.  
Other motifs further upstream of the initiation site (typically ~300 bp) assist in fine-
tuning the expression. More distal elements may also affect the transcription with 
extremes up to 85 kb from coding region [125]. These upstream sequences may be 
either activating or repressing with various mechanisms of action. Repressing the 
transcription may be by interfering with activating motifs or modifying chromatin 
structures [126].  
It is estimated that the human genome harbors more than 2600 proteins with DNA 
binding domains, assumed to be transcription factors [127]. This family of proteins 
constitutes of about 8% of all encoded human proteins, which highlights the importance 
of the genetic regulatory mechanisms.   
The combination of all these factors is a powerful mechanism that allows for specific 
regulation of all genes during different environments for different cells. It is not hard to 
believe that even mutation far out from the coding regions may have great 
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consequences for the regulation of genes, which may not be detected without studying 
a specific cell under the right circumstances. 
 
1.2.4 Splicing 
 
Before the mRNA can be translated into amino acids the transcribed molecule needs to 
be modified to a mature mRNA. The perhaps most advanced step in this procedure is 
the removal of intervening sequences, so called introns. This phenomenon is called 
splicing and is carefully guided by the splice machinery and conserved patterns in the 
sequence. The organelle where splicing takes place is called the splicesome and 
contains the necessary proteins, with the small nuclear ribonucleoproteins (snRNPs) 
being the most crucial elements for splicing. 
The patterns that determine where to splice are called splice sites, which usually consist 
of the nucleotides GU at 5’ end of the intron and AG at 3’ of the intron. About 18 to 40 
nucleotides from the 3’ end of the intron is a motif called the branch point [128]. 
Briefly, splicing starts with the snRNP U1 binding to the 5’ end of intron. This complex 
is then looped to form a structure called lariat, by annealing of 5’ end of the intron to 
the branch point. Additional snRNPs then exactly positions the 5’ end of the intron to 
the 3’ and the ends are ligated through transesterification and the lariat structure is 
released together with the snRNPs. Additionally, splicing may be aided by exonic 
splice enhancers (more common with long introns), which helps to recruit the splice 
molecules to the correct position, or it can be repressed by silencer elements [129].   
Although the splicing of mRNA is exactly regulated by these splice patterns, quite 
often pre-mRNA is spliced in different constitution of the coding exons. This is a 
product of alternative splicing, which is commonly occurring and many genes have 
several variants and some thousands. The mRNA molecule can be differently spliced in 
different tissues; most likely depending on availability of splice factors. In a gene that 
has alternative spliced transcripts, most of the exons are constitutive but some exons 
tend to be excluded, these are called cassette exons and combinations of these may 
result in a wealth of variants. Exons can also be longer or shorter with alternative splice 
sites for both 5’ and 3’ ends. Different promoter structure can result in alternate 5’ start 
exons as well alternate 3’ ends. Intron retention is also resulting in alternate transcripts. 
Splicing can virtually change all functions for a protein, e.g. skipping of membrane 
domain can result in a soluble protein, changing of ligand binding or enzymatic activity 
[129].  
Alternative splicing greatly increase the protein diversity encoded by the human 
genome. Estimates from 60% of all human genes [130] to 95% of all multiexonic genes 
[131] have differently spliced transcripts. Compared to simple organisms, such as 
bacteria, humans have a moderately increase in number of genes and proteins. 
Alternative splicing is most likely one explanation for the complexity of higher 
organisms where the combinatorial approach increases the proteome.  
 
 12 
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5’ UTR 3’ UTR Exon1 Exon2 Exon3 
TATA Promoter Enhancer 
5’ UTR 3’ UTR Exon1 Exon2 Exon3 Intron Intron pre-mRNA AAAA 
5’ UTR 3’ UTR Exon1 Exon2 Exon3 AAAA 
5’ UTR 3’ UTR Exon1 Exon3 AAAA 
Splicing 
Alt. splicing 
Transcription 
Translation to protein 
Nucleus Cytosol 
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Figure 3. A schematic picture of transcription and splicing of DNA to mRNA. 
 
1.2.5 Study design 
 
To find the responsible genetic changes behind disease traits we need to design an 
experiment where genetic markers are compared with a phenotype of the trait. This 
could be done in either experimental animal models of disease or with human patient 
cohorts. The following description will focus on the latter. This includes linkage, cohort 
and case-control studies. 
 
Linkage studies 
Traditionally, family linkage studies have been used to detect responsible mutations 
behind disease. The idea is to find genetic markers that show correlated segregation 
with the trait. To do this it is necessary to follow several generations, which is 
problematic for obvious reasons. Another approach is to study affected siblings with 
the goal of finding a shared genetic inheritance.  
Family studies have historically worked very well with typical Mendelian diseases, 
where a single mutation is often causal for the phenotype. But for complex disease with 
low penetrance the study design is not optimal. Also, in linkage study the resolution is 
very low meaning that a detected locus typically covers several megabases. 
 
Cohort studies 
The cohort study is a very elegant experiment with careful monitoring of exposures for 
the included individuals and is therefore very suited for studying effects of diets, 
lifestyle, medical intervention, work conditions, smoking etc. The prospective cohort 
includes individuals that fulfill certain inclusion criteria regarding exposure and then 
monitors them over time. The exposure and the expected outcome of this cohort are 
recorded until a certain pre-determined number of events has occurred, e.g. disease 
incidence, followed by an evaluation of the exposure and outcome relation (Rothman 
2002). In order to get a sufficient number of individuals with the outcome there is often 
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a need of very large cohorts, specifically if the outcome has a low incidence. This is 
often the case for endemic diseases.  
The clinical trial experiment is a special variant of a prospective cohort where the 
exposure instead is assigned randomly to half of the cohort and the other is the non-
exposure group (the placebo group). This kind of study has a high evidence burden and 
is typically used for measuring drug efficacy.  
A cohort study can also be performed in retrospective, which is in principal the same as 
the prospective but the information of exposure and outcome already exits for some 
reason, usually in different registries. This is the most cost-efficient alternative but is 
limited to data that already exists [132].  
 
Case-control 
Genomic components of the more complex common autoimmune diseases have shown 
to be much harder to assess than for Mendelian disease. Huge progress has been made 
with the case-control design that allows for studying very large number variables for 
many individuals with an increase in both power and resolution. The basic design of a 
case-control experiment is comparing individuals with a certain trait (cases) with 
individuals without this trait but otherwise of similar genetic background (i.e. the same 
population). If carefully designed and performed, this design offers several advantages 
over both the family based and cohort based studies. A case-control study is cost-
efficient since it can be performed with shorter duration than other experimental 
designs and with a smaller study population size than a prospective cohort. The case-
control studies are very suitable for diseases with a fairly late onset that makes 
collection of ancestral material more complicated. It is also easy to include large 
amounts of controls with an increased power as effect at a low cost. Also, when 
studying genetic variance, compared with a family linkage study the amount of 
recombination is much more in a case-control material, resulting in an increased 
resolution of the associated loci.  
A major drawback of case-control is the assessment of the exposure that often is 
subjective. This phenomenon is termed recall bias where affected individuals more 
often tend to exaggerate the exposure then unaffected. This may result in non-specific 
conclusions and is one of the reasons why other cohort studies are deemed with a 
higher evidence burden. Also, the acquisition of controls may also infer errors in the 
study if not properly selected [132].  
 
1.2.6 GWAS – a new paradigm 
 
Large genetic screens, so called genome wide association studies have introduced a 
leap in discoveries of disease-associated variations in the human genome. In short time 
it has become possible to screen all common genetic SNPs of the human genome for 
large case-control studies. Since the introduction of genome scans over 2000 loci have 
been discovered for complex traits [79]. Even with this massive increase of new risk 
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variants, still only a part of the expected genetic contribution for most diseases has been 
discovered. Reason for this may be other un-observed genetic variations such as 
structural variations, epistasis effects or genetic interaction. It may also be a result of 
the high significance threshold, in order to avoid false positives, commonly used for 
these studies.  
A good example of the advancement made possible through GWAS studies is for the 
disease multiple sclerosis. Many of the MS-associated genes are involved in immune 
related pathways and may be subject to therapeutic intervention. Also interesting is the 
two genes in the vitamin D pathways that have been discovered, CYP27B1 and 
CYP24A1. This finding may eventually explain the role of vitamin D in MS and 
perhaps also the increased incidence of disease the farther north the population. 
Another gene, IL2RA, is already a target for therapy, indicating the validity of the 
findings [133].  
For RA similar finding have been made with GWAS. Two successful therapies for RA, 
TNF-inhibitors (e.g. infliximab) and T cell co-stimulation inhibitors (e.g. abatacept) are 
targeted by genetic findings from GWAS (TNFAIP3, CLTA-4 (known prior to GWAS) 
and CD28). However, the function of these variations in relation to disease is still 
unknown for the majority of the associated genes. Many of the genes are pointing to the 
NfKB signaling pathway, which controls transcription and plays a central role in 
regulating the immune system [79]. 
A major limitation of GWAS studies is the underlying design assumption of LD with 
causal polymorphisms. This is derived from the hypothesis – Common disease – 
common variants. This design will miss rare variations since they will most likely not 
be sufficiently linked with genotyped SNPs and to be detected they need to explain a 
big part of the risk. It is currently speculated whether this explains a large part of the 
missing heritability.  
 
1.2.7 Interaction 
 
For the cell to survive and adapt to changes it need to interact constantly. Most of these 
interactions are carried out with proteins binding and affecting other proteins; in 
specific patterns we call pathways. These pathways are essential for us to understand to 
be able to draw conclusions of what happens to the cell when one protein is altered or 
even removed.  
In studying of disease causes we sometimes also use the word interaction for a less 
physically defined phenomenon, to instead describe a statistical dependency of two 
factors that together increases the disease risk/protection. This increased risk is 
compared with the expected effect of both risk factors and if it exceeds this expectation 
this additional risk is attributed to interaction of the risk factors. The two common ways 
of quantifying this is departure from additive and multiplicative effects of interaction. 
In the first model, risk that is additional to the expected sum of the risk from each factor 
separately is considered due to interaction. The percentage of this additional risk of the 
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total risk is used as a measure for interaction effect (attributable proportion, see Figure 
4). In the corresponding regression model, this is represented exclusively by the group 
of individuals having both risk variants versus the group of individuals having either of 
the risk variants [134]. 
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Figure 4. A schematic representation of increased risk due to additive interaction. The attributable 
proportion (AP) is the percentage extra risk, not explained by the sum of separate risks, of the total risk 
(from A and B in the picture). 
 
The multiplicative interaction model expects that the overall risk is multiplied for 
individuals having both risk variants. This is calculated in the regression model by 
inclusion of a multiplicative variable derived from both risk variants. This analysis can 
be used for any dichotomous exposure, such as smoking, phenotypic markers or genetic 
variants (if they are from unlinked loci) [135]. 
None of the models is better than the other, just different ways of modeling the 
potential interaction. 
Interaction between two genetic loci (genetic interaction) is sometimes referred to as 
epistasis, which can be misleading in the way that this implies some underlying 
biological mechanism of interaction. True, this may be so but still it is only a model to 
analyze if there may be a statistical dependence for two risk factors. Any biologically 
relevant interaction is still to be proved if a statistical interaction is found [135]. 
 
1.3 METHODS 
 
The polymerase chain reaction (PCR) completely changed the field of biotechnology 
when it was discovered and developed in the mid-1980s by Kary Mullis, a discovery 
for which he eventually was awarded the Nobel Prize in chemistry (As described in 
[136]). In fact, it is still the corner stone of most tools for studying genetic diversity 
because of its extraordinary versatility. The vast majority of sequencing techniques 
relies on PCR steps and, for instance, one of the recent years largest genetic projects - 
the human genome project, could not have been carried out on a reasonable time line 
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without this discovery. The list of techniques involving a PCR step can be made very 
long and the importance for molecular biology cannot be understated. The following 
three core steps describes a basic PCR: 
Denaturation: The reaction is heated in order to separate DNA strands (~95°C for ~ 
30s) 
Annealing: The temperature is lowered to allow hybridization of oligonucleotides 
(primer, 15-30 nt long) specific for the sequence under investigation  
Elongation: The reaction is adjusted to optimal temperature for the polymerase, which 
is 72°C for the commonly used Taq polymerase. The enzyme synthesizes a 
complimentary a DNA strand with deoxynucleotide triphosphates (dNTPs, nucleotides) 
that is incorporated in 5’ to 3’ direction from the annealed primer.  
These three steps is cycled until a sufficient amount of copied DNA sequence is 
received, usually from 20 to 40 cycles.  
 
1.3.1 Genotyping 
 
Genotyping is the procedure where genetic variation is detected for individuals (see 
chapter on genetics for examples of genetic variation). Many of the genotyping assays 
are depending on the PCR reaction for reaching detectable levels of DNA. The allelic 
discrimination method, commonly used for SNP genotyping, uses PCR of the region 
around the genetic variation and then measures different amount of hybridized probe 
oligonucleotide specific for either allele. The technique is similar for DNA-arrays (or 
SNP-arrays) but the reactions are immobilized on a surface making it possible to carry 
out multiple parallel experiments.  
 
1.3.2 Sequencing  
 
The Sanger sequencing have been instrumental for modern genetic research and is, just 
as PCR, depending on the polymerase enzyme [137, 138]. Basically it is a normal 
polymerase reaction but with the addition of dideoxynucleotides (ddNTP), which when 
incorporated will terminate the elongation process. Originally a sequencing experiment 
was carried out in four reactions with a specific ddNTP that will only terminate the 
sequence for that nucleotide but at random positions. The ddNTP were radioactively 
labeled and the result could be read on a polyacrylamide gel. This procedure was 
greatly enhanced by the use of fluorescently labeled ddNTP, each with a different 
emission. This allows for running the sequence in one reaction and then reading the 
result with capillary electrophoresis.  
The problem with Sanger sequencing is that it is difficult to scale up the technique for 
massive sequencing. The development of another technique, pyro sequencing, has 
however opened the field for array based parallel sequencing [139]. This method 
detects the release of pyrophosphate release with every incorporated nucleotide without 
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the need of a chain termination, as for the Sanger method, and thereby can be used for 
sequencing-by-synthesis.  
  
1.3.3 Transcript expression 
 
The traditional way of measuring mRNA is by reverse transcriptase PCR (RT-PCR). 
Reverse transcriptase is an enzyme that synthesizes DNA sequence from a RNA 
template, that is the reverse of the transcription and hence the name. With this enzyme 
it is possible to create a complimentary DNA (cDNA) strand from the mRNA extracted 
from cells and then apply a normal PCR to amplify the product. To be able to exactly 
measure the template of a PCR the amount of product after every cycle of the reaction 
can be monitored by fluorescence. By using a specific emission threshold, the number 
of PCR cycles for the targets to reach this threshold is used to calculate the initial 
amount. This threshold is set so that the read off is in the exponential phase of the PCR, 
thus making it possible to compare different reactions. This procedure is called real-
time PCR, or quantitative PCR (qPCR) and is a very precise way of measuring the 
amount of mRNA. There are two major techniques in use for qPCR: the double 
stranded DNA fluorescent dye and a reporter probe method. The first method uses, in 
addition to the normal PCR reagents, fluorescence dye that emits light at a specific 
wavelength upon binding to double-stranded DNA. By this it is possible to follow the 
increase of the double stranded product after every cycle of the PCR reaction. A 
common dye for this is SYBR green. The other method uses a probe specifically 
designed to hybridize with the PCR product. To the probe a fluorescent reporter and a 
quencher is attached at separate ends and when the polymerase reaches the hybridized 
probe the quencher and reporter are separated by breakdown of the probe. This allows 
for emission of light upon excitation and the fluorescence of reporters are proportional 
to the amount of produced PCR product. [140] 
The rapid development of DNA sequencing has made it feasible to instead sequence all 
the mRNA from a sample and use the number of sequence reads as proxy for the 
amount. This is a very promising technique that has the advantage of covering all 
targets at once and is rapidly exchanging the array-based methods [141, 142].   
 
1.4 CONCLUSION OF INTRODUCTION 
 
With this survey I believe I have made the following statements valid as a background 
for my study: 
1. Rheumatoid arthritis is genetically heritable disease that indicates that at least some 
patients must have a more or less common genetic component(s). 
2. The human genome is highly diverse which allows for genetic studies. 
3. There is a huge regulatory potential outside the coding regions, which may be very 
important for genetic contribution to disease. 
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4. The regulatory features in these regions have effects on expression of genes and also 
on the composition of transcripts (alternative splicing).  
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2 STUDY POPULATIONS 
 
All the included papers in this thesis are using data from the Swedish Epidemiological 
Investigation of Rheumatoid Arthritis (EIRA). This is a population based case-control 
cohort that includes the major part of incident cases of RA from the middle region of 
Sweden starting from the year 1996. For each included patient in the EIRA study, 1-2 
controls are selected based on age, gender and residence area. All included individuals 
are asked to fill in an extensive questionnaire and leave blood samples for DNA 
extraction. [32, 97]. From a small subset of these individuals we have also collected 
blood for mRNA extraction.  
This thesis also includes several other cohorts that are described in the included papers. 
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3 AIMS 
 
The aim of this thesis is to explore the RA risk associated genes CIITA, PTPN22 and 
DCIR to get further knowledge about the role for development of disease. 
The first part of this thesis is devoted to studies of CIITA. In papers I and II we aimed 
to replicate and to study in detail the association of CIITA with RA. The first paper 
includes an updated meta-analysis with evidence of association for a novel marker in 
the locus and a relationship with SE. In the second paper this relationship is further 
investigated in additional cohorts. 
In paper III we aim to explain the biological background for the previous found 
association of CIITA expression with the associated risk variant by specifically 
targeting the different promoter isoforms of the gene.  
This is followed by similar studies of expression of mRNA isoforms for DCIR and 
PTPN22 with the hypothesis that the risk variants may have different effect on the 
specific transcripts, stemming from alternative splicing the genes, which may be 
specifically affected and it may suggest mechanisms for disease development.  
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4 MAIN RESULTS 
 
This section is a summary of the results presented in papers I-V in the end of this thesis.  
 
4.1 PAPER I: CIITA GENE VARIANTS ARE ASSOCIATED WITH 
RHEUMATOID ARTHRITIS IN SCANDINAVIAN POPULATIONS 
 
Ever since a variant in the CIITA promoter, SNP rs3087456 (-168A/G), was discovered 
to be in association with RA and MS [55] there have been conflicting reports whether it 
is an actual risk factor for the disease RA or not. A meta-analysis from 2008 [60] 
concluded that the overall evidence was negative, but findings for other disease than 
RA showed association, specifically for MS [43, 61, 62] and also extending this 
association for other markers in locus. Given this, and the observation that the effect is 
moderately strong in some population (Swedish: OR 1.19, 95% CI 1.02-1.38 [55]; OR 
1.46, 95% CI 0.80–2.66 [43]; Japanese: OR 1.47, 95% CI 1.16-1.87 [58]) where it is 
abolished in other [56, 57, 143] we believed a thorough investigation was warranted. 
Therefore we extended the data for rs3087456 in the Swedish EIRA cohort (partly used 
in [55]) and added a Norwegian cohort with RA (n=819), a juvenile idiopathic arthritis 
(JIA; n=524), a type 1 diabetes (T1D; n=1211) with controls (n=2149). We also tested 
a novel risk variant, rs8048002, which has indicated a strong association with risk for 
Addison’s disease [66], suggesting it may be a better marker for disease. 
CIITA rs3087456 was significantly associated with RA for the Norwegian cohort (GG 
vs GA+AA, OR 1.50, 95% CI 1.10-2.05) and also in the combined material of Swedish 
and Norwegian cohorts (OR 1.37, 95% CI 1.11-1.69), Table 2.  
Also rs8048002 was significantly associated with RA, but none of the markers 
exhibited association with JIA and T1D (Table 1 and Table 2 in paper I).  
We also performed an updated meta-analysis for rs3087456 with all available studies 
published, which supported association of CIITA with RA (p=0.02). The effect was, as 
anticipated, stronger in the Scandinavian populations (including three independent 
cohorts), which was evident from meta-analysis of subgroups (OR 1.39 (95% CI 1.16-
1.66), p=4x10-4, Figure 5).  
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Table 2: Association analyses of rs3087456 in Scandinavian patients and controls 
Rs3087456   Genotype count (%) MAF % GG vs. GA+AA 
Material n GG GA AA G OR (95% CI) P-value 
Norway 
RA 799 68 (8.5) 271 (33.9) 460 (57.6) 25.5 1.50 (1.10-2.05) 0.0093 
JIA 501 28 (5.6) 171 (34.1) 302 (60.3) 22.7 0.96 (0.63-1.46) 0.84 
T1D 1190 84 (7.1) 443 (37.2) 663 (55.7) 25.7 1.23 (0.92-1.64) 0.16 
Control set #1 932 51 (5.5) 354 (38.0) 527 (56.5) 24.5   
Control set #2 1112 68 (6.1) 424 (38.1) 620 (55.8) 25.2   
Controls all 2044 119 (5.8) 778 (38.1) 1147 (56.1) 24.9   
Sweden new*  
RA 1212 91 (7.5) 427 (35.2) 694 (57.3) 25.1 1.32 (0.90-1.93) 0.16 
Controls 706 41 (5.8) 254 (36.0) 411 (58.2) 23.8   
Sweden all* 
RA 2479 174 (7.0) 876 (35.3) 1429 (57.6) 24.7 1.28 (0.97-1.70) 0.081 
Controls 1332 74 (5.6) 448 (33.6) 810 (60.8) 22.4   
Combined new* 
RA new** 2011 159 (7.9) 698 (34.7) 1154 (57.4) 25.3 1.42 (1.12-1.81) 
0.0043; 
corrected: 
0.017 
Controls new 2750 160 (5.8) 1032 (37.5) 1558 (56.7) 24.6   
Combined all* 
RA all*** 3278 242 (7.4) 1174 (35.0) 1889 (57.6) 24.9 1.37 (1.11-1.69) 
0.0030; 
corrected: 
0.012 
Controls all 3376 193 (5.7) 1226 (36.3) 1957 (58.0) 23.9   
n refers to the number of successfully genotyped individuals. P-values are uncorrected and are for 
Pearson χ2 test. CI, confidence interval; JIA, juvenile idiopathic arthritis; MAF, minor allele frequency; 
OR, odds ratio; RA, rheumatoid arthritis; T1D, type 1 diabetes. *”New” refers to previously 
uncharacterised Swedish samples; “All” includes samples reported in [55]. **Meta-analysis, fixed effects 
model; heterogeneity: Chi²=0.28, df=1 (P=0.59); I²=0 %. ***Meta-analysis, fixed effects model; 
heterogeneity: Chi²=0.56, df=1 (P=0.45); I²= %. This table is modified from Table 1 in paper I where the 
full table including additional analysis can be found.  
 
When stratifying the Norwegian and Swedish cohorts by SE status we detected an 
increased combined risk for disease for rs3087456 and rs8048002 in the SE-positive 
and SE-negative groups, respectively (Table 3 in paper I). This interesting relationship 
with SE alleles, the strongest genetic predisposition marker for RA, was analysed in 
detail in paper II.  
Conditional regression analysis could not distinguish which of the variants, rs3087456 
or rs8048002, was the better marker for disease (supplementary Table 2 in paper I). 
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Study  or  Subgroup
Scandinavian  studies
Subtotal  (95%  CI)
Heterogeneity:  Tau²  =  0.00;;  Chi²  =  0.53,  df  =  3  (P  =  0.91);;  I²  =  0%
Test  for  overall  effect:  Z  =  3.55  (P  =  0.00038)
British  studies
Eyre  2006
Harrison  2007
Plant  2009
Subtotal  (95%  CI)
Heterogeneity:  Tau²  =  0.00;;  Chi²  =  2.26,  df  =  2  (P  =  0.32);;  I²  =  12%
Test  for  overall  effect:  Z  =  0.07  (P  =  0.94)
Spanish  studies
Dieguez-­Gonzalez  2009
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Figure 5. An updated meta-analysis of CIITA -168GG as a risk factor for RA. The analysis is performed 
in subgroups based on origin of population combined with a complete analysis of all available 
populations. Combined associations were tested with a random effects model. RA, rheumatoid arthritis; 
CI, confidence interval. 
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4.2 PAPER II: INTERACTION ANALYSIS BETWEEN HLA-DRB1 SHARED 
EPITOPE ALLELES AND MHC CLASS II TRANSACTIVATOR CIITA 
GENE WITH REGARD TO RISK OF RHEUMATOID ARTHRITIS 
 
The role of CIITA, a key regulator for the human leukocyte antigen (HLA) class II 
proteins, for disease risks is interesting due to the strong effect of HLA on autoimmune 
disease. In paper I, we re-evaluated the association of CIITA with RA and showing a 
possible population dependent mode of action. We also detect an increased level of risk 
for developing RA with CIITA risk variants in the subgroups defined by the presence of 
SE alleles. The risk conferred by rs3087456 was stronger in the SE-positive group. To 
further study this effect and evaluate whether this increase is the result of an interaction 
of the risk variants we performed a detailed analysis of interaction for HLA-DRB1 (SE) 
alleles and CIITA (rs3087456) in four independent cohorts with a total number of 6649 
RA patients and 5118 controls.  
We could not establish a consistent significant interaction (additive or multiplicative) 
between the risk factors rs3087456 and SE alleles in the cohorts studied (Table 4).  
The result was similar when individuals were stratified by presence of ACPA. The 
specific alleles for SE were also scrutinized where it seems that a small effect was 
detected for the DRB1*04 allele in the Swedish cohort but it did not replicate in the 
Norwegian cohort (Table 3). 
The variant rs8048002 did not give reliable results since the low minor allele frequency 
resulted in very small data groups.  
A screen of 22 SNPs in the CIITA locus did not reveal any other interacting variants. 
 
Table 3. Summary data of the interaction analysis for HLA-DRB1 SE allelic groups and SNP rs3087456 
for the Swedish cohort 
Group rs3087456 and: AP CI 95 low CI 95 high P value 
All SE (yes/no) 0.2 -0.2 0.5 0.5 
 DRB1*01 -0.3 -1.2 0.6 0.5 
 DRB1*04 0.2 -0.2 0.6 0.3 
 DRB1*10 0.05 -1.5 1.6 0.9 
ACPA+ SE (yes/no) 0.3 -0.05 0.6 0.1 
 DRB1*01 -0.2 -1.1 0.7 0.7 
 DRB1*04 0.3 -0.1 0.6 0.2 
 DRB1*10 -0.1 -2.0 1.8 0.9 
Additive interaction is presented as attributable proportion (AP) with 95% confidence interval (CI). For 
additional analysis see supplementary table S5. SE = shared epitope; ACPA+ = anti citrullinated protein 
antibody positive RA patients. 
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Table 4. Risk of developing RA for combinations of the HLA-DRB1 SE and rs3087456 alleles in 
Swedish, British, Dutch and Norwegian cohorts 
CIITA 168GG SE Ca/Cont OR 95% C.I. AP (95% C.I.) Add Mult 
Sweden all     0.2(-0.2-0.5) P=0.4 P=0.9 
No None 571/582 1.0 …    
No Any 1655/630 2.7 2.3-3.1    
Yes None 41/30 1.4 0.9-2.3    
Yes Any 117/33 3.6 2.4-5.4    
Sweden ACPA+     0.3(-0.05-0.6) P=0.1 P=0.4 
No None 222/582 1.0 …    
No Any 1205/630 5.0 4.2-6.0    
Yes None 11/30 1.0 0.5-2.0    
Yes Any 86/33 6.8 4.4-10.5    
Norway all     0.4(0.03-0.7) P=0.03 P=0.4 
No None 186/682 1.0 …    
No Any 533/751 3.8 2.1-3.2    
Yes None 14/44 0.9 0.6-2.2    
Yes Any 50/43 3.1 2.7-6.6    
Norway ACPA+     0.4(0.05-0.7) P=0.02 P=0.7 
No None 56/682 1.0 …    
No Any 363/751 6.2 4.4-7.9    
Yes None 5/44 0.7 0.5-3.6    
Yes Any 35/43 5.5 5.9-16.7    
UK. all     -0.2(-0.7-0.3) P=0.4 P=0.7 
No None 429/638 1.0 …    
No Any 1354/529 3.0 3.2-4.5    
Yes None 36/57 0.9 0.6-1.5    
Yes Any 97/46 2.1 2.2-4.5    
UK ACPA+     -0.1(-0.5-0.3) P=0.7 P=0.6 
No None 198/638 1.0 …    
No Any 1023/529 5.9 5.1-7.5    
Yes None 13/57 1.0 0.4-1.4    
Yes Any 79/46 4.3 3.7-8.2    
Netherlands all     -0.3(-1.4-0.8) P=0.6 P=0.8 
No None 136/146 1.0 …    
No Any 9/11 2.6 2.2-4.1    
Yes None 321/116 1.2 0.4-2.2    
Yes Any 20/10 4.3 1.0-4.8    
Netherl. ACPA+     -0.4(-1.7-1.0) P=0.6 P=0.8 
No None 27/146 1.0 …    
No Any 2/11 5.9 3.7-9.6    
Yes None 127/116 1.4 0.2-4.7    
Yes Any 8/10 9.9 1.6-12.0    
Evidence for additive and multiplicative interaction is displayed as significance (P value) of deviation 
from expected risk given no interaction. AP = attributable proportion; SE = shared epitope alleles; OR = 
odds ratio; ACPA = anti citrullinated protein antibody positive; CI = confidence interval. 
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4.3 PAPER III: GENETIC CONTROL OF ISOFORM EXPRESSION OF 
HUMAN MHC CLASS II TRANSACTIVATOR 
 
It was previously shown that the CIITA risk variant rs3087456 was correlated to the 
mRNA expression of the gene [55]. Interestingly, CIITA has four promoter isoforms 
that are expressed at various degrees in different cell types [71]. This probably gives an 
advantage in specific regulation of the HLA class II genes where different promoters 
are under control of different transcription factors. With this complexity we felt the 
need of quantifying the isoforms separately since they may be affected by different 
mechanisms. We characterized the expression of isoforms CIITA_pIII and CIITA_pIV 
in samples from the EIRA cohort and an asthma cohort. Isoform CIITA_pI was below 
detection limit in our material and CIITA_p2 is rarely expressed (for instance detected 
in a human melanoma cell line [73]).  
For CIITA_pIII the expression was similar for RA patients and controls but this was not 
the case for CIITA_pIV, where patients had significantly higher expression (Figure 1a 
and 1b in paper III). For PBMCs stimulated with IFN-gamma, the expression was 
higher for both CIITA_pIII and CIITA_pIV for patients (Figure 1b and 1d in paper III). 
Also, the expression for stimulated cells increased more for the patients samples 
compared to controls (Figure 1e and 1f in paper III). In the cohort with asthma patients 
and controls we found no difference in expression between patients and controls 
(Figure 2 in paper III). 
Perhaps more interestingly, we detected a correlation with genotype and CIITA 
expression. This was the most pronounce for CIITA_pIV, but could also be seen for 
CIITA_pIII in stimulated cells. The expression of CIITA_pIII and CIITA_pIV for 
controls and for the samples in cohort of asthma patients and controls was not 
correlated with the SNP rs3087456 however.  
For patients, we correlated a further 22 SNPs in the CIITA locus with the isoform 
expression and could detect other SNPs significantly associated with expression, 
primarily in the promoter region (Table 1 in paper III). This association was coinciding 
with the allelic association with risk of developing RA (Figure 6). This may be due to 
extensive LD in the region (Figure 6) but is still a sign of consistence for our finding.  
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Figure 6. The middle part is a graph representing the association (-log p-val) of SNPs (n = 22) with 
mRNA expression (dashed line) and with risk for disease (continuous line) for the CIITA locus. Under the 
graph is a LD-plot where numbers correspond to r-square values and above is a schematic illustration of 
the CIITA isoforms exonic-intronic structure.  
 
4.4 PAPER IV: DIFFERENTIAL EXPRESSION OF TRANSCRIPTS FOR 
THE AUTOIMMUNITY-RELATED HUMAN DENDRITIC CELL 
IMMUNORECEPTOR 
 
In this paper we present result of an expression study for the gene DCIR in peripheral 
blood mononuclear cells focusing on the four known expressed gene transcripts. The 
study was conducted in mRNA samples from the EIRA cohort with replication in a 
cohort of asthma patients.  
The mRNA expression was evident for all four splice forms of DCIR in PBMC and we 
could not detect any differences for RA patients versus controls (Figure 1a and figure 2 
in paper IV). During the basic investigation of splice forms we could detect a novel 
fifth variant in 12.5% of all individuals and sequencing revealed that this form was 
lacking exons three and four (Figure 7).  
 
Figure 7. A gel picture of stained PCR product from of all known splice forms of DCIR. The splice 
forms were all amplified by the same primer-pair. In a), the four previously known transcripts are shown 
and in b) the additional fifth transcript is shown. All PCR products were of the expected size and the 
structure was confirmed by sequencing.  
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In line with the assumed function of DCIR, as part of an inhibitory cell-signaling 
pathway, we could show that it was significantly down regulated with IFN-gamma 
stimulation of cells (Figure 3 in paper IV). This down regulation was similar for all the 
targeted splice forms and was not affected by disease status.  
To assess whether the RA associated variants could have an effect on the mRNA 
expression we used a set of 19 SNPs for patients and 6 SNPs for controls across the 
DCIR locus. This revealed a clear association of the fourth DCIR splice form with 
variants in the locus (Figure 8), where the SNP rs2024301 was the strongest 
(patients P=0.0009, controls P= 0.0078 and combined samples P=6.5*10-6), Kruskal–
Wallis, Figure 5 in paper IV). We could also replicate this finding in the smaller cohort 
of asthma cases and controls. 
We could not see an effect on the expression when stratifying the patients by ACPA 
status or any other disease measure.  
 
Figure 8. The graph represents association of SNPs with expression of DCIR transcripts from analysis of 
both RA patients and controls. SNPs marked with an asterisk are associated with ACPA negative RA. 
The upper part of the figure shows the exonic configuration in genomic DNA of DCIR_v1.  
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4.5 PAPER V: THE BALANCE OF EXPRESSION OF PTPN22 SPLICE 
FORMS IS SIGNIFICANTLY DIFFERENT IN RHEUMATOID 
ARTHRITIS PATIENTS COMPARED WITH CONTROLS 
 
Genetic variation in protein tyrosine phosphatase non receptor 22, PTPN22, has 
repeatedly been shown to associate to autoimmune diseases where the risk is detected, 
mainly, through the SNP rs2476601. This is a non-synonymous polymorphism 
affecting the aminoacid at position 620 in the protein with a change from arginine to 
tryptophan (R -> W). This difference in the protein has been associated with an 
increased function of the phosphatase. This gain of function leads to impaired receptor 
signaling for T-cells [51] and B-cells [53]. There are, however, other variants in the 
locus that has been shown to associate with disease independently from rs2476601 
[144, 145], which is evidence that there could be other mechanisms for PTPN22 
involvement in the risk for disease.  
In order to look for other mechanisms by which disease associated polymorphisms can 
exert their effect we measured the level of mRNA expression of two transcripts from 
PTPN22 for which it has been shown there are corresponding protein isoforms, 
PTPN22_v1 (NM_015967.5) and PTPN22_v4 (NM_012411.3) [146]. The 
measurement for the longer of these two, considered normal, transcripts also involved 
two other transcripts (PTPN22_v2 and PTPN22_v3 (NM_012411.4 and 
NM_001193431.1 respectively)), which were discovered recently. An illustration of the 
PTPN22 transcripts with functional domains can be seen in Figure 9. This study was 
conducted with three independent cohorts of RA patients and controls for exclusion of 
sampling and sample preparation errors and qPCR measurements was conducted at 
different labs.  
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Figure 9. A genomic illustration of PTPN22 at human chromosome 1p32. Hs00247352_m1 and 
Hs00249262_m1 are assay numbers (Applied Biosystems). The four SRC Homology 3 (SH3) domains 
are denoted by P1-P4 and are typically involved in protein-protein interaction. Known binding sites for 
C-terminal Src kinase (Csk) and CD2-binding protein 1 (CD2BP1) are located in P2 and P4 (C-terminal 
homology (CTH) domain) respectively. The C-terminus of Lyp1 contains a consensus motif for cyclin-
dependent kinase 1 (CDK1). Exonic and basic domain structure is deduced from Ensembl (Ensembl 64: 
Sep 2011)[147] and UCSC Genome Browser (GRCh37/hg19 assembly)[147, 148] [148] and published 
articles [146, 149]. 
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We discovered and could replicate a consistent difference in expression of PTPN22 
splice forms for patients and controls in all the three RA cohorts (Table 5). Patients had 
in general a higher expression of PTPN22_v1 and lower expression of PTPN22_v4. 
Using the ratio for each individual of the expression for these two transcripts the 
difference was even more pronounced.  
 
Table 5. Expression of PTPN22 transcripts in PBMCs from cohort I, II and III. 
Median relative quantity values   
    Control group RA patient group P-value a 
Cohort I  n=44 n=44  
 PTPN22_v4 1.05 0.85 0.08 
 PTPN22-long 1.03 1.20 0.006 
 long/v4 1.01 1.42 6x10-9 
Cohort II  n=19 n=47  
 PTPN22_v4 0.98 0.96 0.85 
 PTPN22-long 0.97 1.07 0.25 
 long/v4 0.96 1.15 0.02 
Cohort III  n=48 n=48  
 PTPN22_v4 0.96 0.72 1.2x10-4 
 PTPN22-long 0.97 0.92 0.2 
  long/v4 1.04 1.24 0.01 
a P-value for comparison of patient group and control group, Mann-Whitney test. 
 
This difference was abrogated in IFN-gamma stimulated cells where the healthy 
controls behaved similarly as the patients (Table 2 in paper V). We could control for 
effect of medication in cohort 1 since not all individuals were on treatment at the time 
of sampling. Also, we performed cell experiments with methotrexate treatment of 
PBMCs from healthy controls and also Jurkat and Daudi cell lines (T lymphocyte and 
B lymphoblast cell lines respectively) and the results showed no trend for up- or down-
regulation of the ratio for PTPN22 expression by this treatment. 
We also measured PTPN22 transcripts in a multiple sclerosis (MS) cohort (patients 
n=60, controls n=44) and the difference between MS patients and controls were 
inversed from RA patients and controls. This marked difference from RA coincides 
with the fact that PTPN22 is not a risk factor for MS disease.  
Of the studied risk factors, neither the disease associated SNP rs2476601 nor any other 
variant in the locus (25 SNPs spanning Chr1:114114146-114303491) were in 
correlation with the expression of the PTPN22 transcripts or the ratio of those. 
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5 DISCUSSION 
 
5.1 OVERVIEW 
 
In this thesis work, variants in three seemingly separate genetic risk genes have been 
studied thoroughly. The aim was to expand and consolidate the evidence for a disease-
causing role of the current genes and to explain possible biological mechanisms for 
previously found associations.  
Single nucleotide polymorphisms (SNPs) are central to conducting large well-powered 
studies of common complex disease. The last five years, genome wide association 
studies (GWAS) has pushed our knowledge about the underlying genetic contribution 
for many diseases with several new potential risk loci in our genome to study further 
[79]. It is, however, in most cases unknown exactly how the associated risk variants 
acts to increase the risk for disease. Also, it is not always trivial to connect an 
associated SNP with a particular candidate gene locus, which could be evaluated for a 
studied effect.  
The genes of topic are, at varying degree, established risk factors for RA.  
PTPN22 
The risk variant rs2476601 in PTPN22 has been replicated several times for RA and is 
considered the strongest genetic risk factor outside the major histocompatibility 
complex for autoimmune disease, showing association to several diseases, such as type 
1 diabetes, systemic lupus erythematous, Hashimoto’s thyroiditis, Grave’s disease, 
Addison's disease, myasthenia gravis, vitiligo, systemic sclerosis juvenile idiopathic 
arthritis and psoriatic arthritis (reviewed in [150]).  
CIITA  
The effect of variants in CIITA for RA is still under debate with conflicting results in 
different populations.  However, there are reports of variants in CIITA as risk factors 
for MS [43, 55, 59, 61, 62], SLE [151] and Addison’s disease [66]. Shared risk factors, 
pleiotropy, is a phenomenon that is often seen for autoimmune disease which increase 
the likelihood that CIITA has a true effect for RA. 
DCIR 
The DCIR gene is the least investigated among these three targets. With the 
background from a rodent model for oil-induced arthritis this locus was associated with 
sero-negative RA [75]. This is particularly interesting since there are very few genetic 
candidates for this subgroup. And perhaps even better evidence, mice with a knockout 
for the DCIR gene develops autoimmune like disease [152]. 
 
Our intentions have been, for each of these autoimmune associated loci, to enhance the 
connection to disease with further genetic and gene expression analyses. 
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5.2 DCIR EXPRESSION 
 
For DCIR we could show that a transcript variant was significantly correlated with the 
disease associated polymorphism. This transcript variant is a putative soluble protein, 
which could have an opposing effect on the normal signaling pathway for DCIR. 
The lack of replicate studies for DCIR is not very surprising. Firstly, the effect found 
between RA patients and healthy controls was small, (1.27 (95% CI 1.06–1.52)) and to 
replicate this with 80% power in a candidate gene study, it would need around 1000 
patients and 1000 controls at significance level 0.05 [153]. In most cases, a lower 
significance level is wanted with the extreme in GWAS studies, where 5x10-7 is 
considered a reasonable threshold for significance [154], which results in that a larger 
study population is needed (>3000 patients in this case). Secondly, the association was 
found for the ACPA negative subpopulation of RA, which in Swedish EIRA cohort 
represents about 40% of all patients. In other cohorts this is many times smaller or 
sometimes non-existing. These two facts combined hamper the likelihood of a 
successful replication of this risk locus.  
There are, however, a couple of facts that speak in favor that DCIR is involved in the 
etiology of RA. DCIR protein is abundantly expressed in the synovial fluid and tissue 
of RA patients; it is not detected in the joint of healthy individuals. This expression is 
decreased with local glucocorticoid treatment [155]. DCIR protein is expressed on 
many professional antigen presenting cells, but perhaps the most interesting is 
expression on both CD4+ and CD8+ T cells. This expression was shown to be 
restricted to cells from synovial joint compared with cells from blood [155]. Also, IFN-
alpha seems to be interesting for regulation of DCIR. INF-alpha induces a reduction 
(78%) of cell surface DCIR expression and when triggering DCIR it down-regulates 
TLR9-mediated IFN-alpha production by pDCs [156]. IFN-alpha is a pro-inflammatory 
cytokine, which is highly expressed in the RA joint and is also co-expressed with 
TLR3/7 [157]. 
Additionally, we have observed a clear co-expression of DCIR and FOXP3 on T cells, 
which is further enhanced for cells in synovial fluid. Interestingly, these 
DCIR+FOXP3+ T-cells were not CD25bright. This data suggests that there may be a 
unique subset of Tregs distinguished by DCIR+FOXP3+CD25low specifically in the 
rheumatic joint (unpublished data). 
In the paper included in this thesis, we showed that there was no difference of the 
mRNA expression of DCIR in circulation for a sufficiently sized cohort of RA patients 
and matched controls, which indicates that the effect may be confounded to the actual 
site of inflammation – the rheumatic joint. This is interesting since the expression of all 
DCIR mRNA isoforms was down regulated by IFN-gamma in our study and previous 
studies has shown a similar down regulation followed by IFN-alpha [156].  
The correlation of rs2024301 with DCIR expression is equal for patients and controls 
gives a hint that this is a biological effect of the SNP and not biased by the disease 
status. A possible functional effect for the DCIR RA associated allele was presented as 
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significant lower expression of the shortest mRNA splice form. This isoform lacks the 
membrane-binding domain and could give rise to a potentially soluble gene product. 
The DCIR full length variant is assumed to have an inhibitory function (supported both 
by the ITIM motif and by the down regulation in cells treated with IFN-gamma) where 
the soluble form may counteract this. Less of this soluble form may therefore lead to a 
higher inhibitory cell signaling.  
 
5.3 TRANSCRIPT BALANCE FOR PTPN22  
 
PTPN22 R620W is without a reasonable doubt associated to autoimmune disorders, 
which is not only reproduced in several diseases with a strong antibody component but 
also across several different populations where this polymorphism exists [41]. This 
latter fact supports a causal and functional effect of the SNP. There is however no clear 
mechanism for how this mutation acts to favor disease. 
Studies of primary human cells suggest that R620W is a gain of function mutation with 
an increased de-phosphorylation and inhibitory function as result [51, 52, 158]. In 
opposite, in Jurkat cells (Lymphoma T cell line), co-expression PTPN22 W620 and 
CSK (C-terminal Src kinase) have an increase phosphorylation of the downstream 
MAPK Erk compared to wild-type R620 [54]. This result implies a loss of function 
with an increased effect of TCR signaling. With these effects pointing in the opposite 
direction, when it comes to the effect of R620W, it is not impossible that the mutation 
may exert both positive and negative regulation in the different pathways in same or 
different cells. The proposed interaction of LYP and CSK, which stems from results 
from the homologous mouse protein Pep studies [49, 50], could have different effect on 
the LYP isoforms or possibly no effect on the shortest.  
PTPN22 is expressed exclusively in a majority of the hematopoietic cell [159], with the 
highest expression in NK cell and neutrophils and lowest in monocytes and CD4+ T 
cells [41]. This may, however be subject to change with activation of cells. 
Interestingly, tissue from thymus has been shown to express all LYP isoforms, which 
may point to an important function of the transcripts for the positive and negative 
selection of T cells.  
In our work we illustrate that the expression of PTPN22 is different for RA patients 
compared with healthy individuals and that this is specific for the different isoforms. If 
PTPN22 may indeed have an ambiguous role, with both a gain of function and a loss of 
function for different pathways, an altered balance between transcripts may increase the 
direction of autoimmunity. Also, exactly how the R620W mutation affects the 
enzymatic capability of PTPN22 is unclear since the position is well outside the 
catalytic domain (see Figure 9). This mutation may very well have different effect for 
the different isoforms or just be in LD with a causal variant.   
Another interpretation of our findings may be that we see a marker of active 
inflammation for RA patients where this is not the case for MS patients which show an 
opposite balance of isoforms compared with controls. If this is true, it is very likely that 
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this difference in expression is similar for other autoimmune diseases that associate 
with PTPN22 R620W. In conclusion, the altered balance between isoforms could be 
used as a marker for inflammation and even useful for diagnosis of disease. 
 
5.4 CIITA 
 
5.4.1 CIITA is re-associated to RA 
 
The fact that CIITA has a well-defined function in the expression of class II HLA, 
including HLA-DRB1, gives it a promising role as a gene candidate to study for 
autoimmune disease. When a variant in CIITA, -168G (rs3087456), was presented as 
risk factor for RA, MS and MI (myocardial infarction) [55] it became a target for many 
replication studies. These studies gave an inconclusive picture and when used in a 
meta-analysis by Bronson et al., 2008, the combined results was that there was no 
evidence regarding CIITA as a risk locus. There was, however, still evidence for an 
effect in the Swedish population [43, 55] that needed to be followed up, particularly 
since evidence for CIITA involvement in other diseases is growing [61, 63-66, 151]. 
When extending the CIITA research with data from Norwegian population, the results 
points in the same direction as for the Swedish population and with an updated meta-
analysis, the CIITA -168G risk variant is a marginally significant risk factor for RA. In 
the Scandinavian population, this is much more evident (3551 patients and 4827 
controls; OR 1.39 (95% CI 1.16-1.66), P=3.8x10-4; no heterogeneity: I2=0%, P=0.91). 
It seems, not exclusively, that CIITA plays a bigger role as risk factor in northern 
populations, either because of interaction with unknown environmental factors or due 
to difference in allelic frequency and higher statistical power to detect association. 
Mutations that exist in several populations are very seldom risk factors for only a 
certain subset of these, but even so, this seems to be the case for the risk variant -168G 
in RA. One of likely explanations for this is that rs3087456 is not the causal SNP for 
this association; rather it is in linkage disequilibrium (LD) with a variant that has direct 
or indirect functional effect on disease risk. If this causal variant has a low frequency in 
the population, it may even be missing in some, even small differences in LD may 
affect the association to disease [160]. 
It should also be noted that heterogeneity between different cohorts, not only in the 
inclusion of cases but also controls, might infer these different conclusions. For 
instance, we see a clear difference in association for subgroups determined by the SE 
status; rs3087456 has a stronger effect in the SE-positive subgroup  
(SE-positive: OR 1.58 (95% CI 1.20-2.10), P=0.0013 vs all RA: rs3087456 OR 1.37 
(95% CI 1.11-1.69), P=0.0030). This data is extended in paper II. 
We also detected a, for RA, new risk variant, rs8048002, in the Norwegian cohort and 
replicated it in the Swedish population. We could not show that this variant was 
independent of rs3087456 and the relation between these risk variants is unclear. 
 
   37 
5.4.2 Interaction with MHC class II 
 
The discovery that CIITA has stronger effect in the subgroup of SE-positive patients 
prompted us to perform a detailed investigation whether the CIITA locus is statistically 
interacting with HLA-DRB1 locus, in other words: do individuals carrying risk variants 
in both loci have an unexplained increase of risk, not expected by merely adding the 
separate risks. If they are dependent risk factors, this should be the case. We already 
know they are biologically interacting and it could be that certain alleles from both loci 
are driving the disease more strongly. 
In this work we were using four cohorts from Swedish, Norwegian, British and Dutch 
populations. As for the previous study, results were differing between populations but 
the overall conclusion was that a significant interaction could not be established. Since 
SE is a synthetic marker for a specific set of HLA-DRB1 alleles, these were also focus 
for deeper analysis of interaction with CIITA but with no conclusive results.  
It seems that the relationship of CIITA and SE alleles that was found in paper I is not 
due to a significantly large interaction. Interestingly, the other variant studied in paper I, 
rs8048002, had a stronger effect in the ACPA negative subgroup. Since LD between 
markers indicates a relation (D´=0.96 and r2=0.20 in the Swedish cohort) this opposite 
relation is surprisingly and the effect of SE should therefore be interpreted with caution. 
However, a relation for CIITA and DRB1 has been observed in another study of a MS 
cohort [61] where a dependency for CIITA rs4774 and HLA-DRB1*1501 is described. 
This result indicates that there may be more to discover for these two risk loci and that 
we need to refine our hypothesis.  
 
5.4.3 Expression of CIITA isoforms 
 
As seen in the original work describing the association of CIITA with disease [55], the 
risk variant correlates with CIITA mRNA expression for IFN-gamma stimulated 
PBMCs and also downstream levels of class II HLA mRNA. In paper III we investigate 
if this effect from -168G variant (rs3087456) specifically affects CIITA isoforms. We 
could establish that this variant was correlated to both CIITA_p3 and CIITA_p4 but 
with a more pronounced effect for _p4. This could mean that both these promoters have 
a common transcription factor binding site that is upstream of the transcription 
initiation site. Or, it could be more several mutations in linkage affecting both 
promoters in a similar fashion. Due the extensive and strong LD pattern in the promoter 
region of CIITA this is difficult to discern. This LD block is most likely also the reason 
why we see an extensive overlap between the SNPs correlating with isoform expression 
and the SNPs associating to disease (Figure 6). The well-conserved LD block also 
extends a good portion 5’ upstream from the first CIITA promoter exon indicating that 
this region may contain important enhancer elements for transcription. 
If the SNP -168G (rs3087456) would be a true causal variant, with an effect on CIITA 
expression, it would most likely not effect transcription of both isoforms. More likely, 
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another variation in linkage with -168G is responsible for both association to disease 
and correlation to expression. This conclusion also fits with our results presented in 
paper I.  
It is interesting that we only detect the correlation for expression and genotype for 
patients. It could be argued that a variant should have the same effect regardless of 
diagnosis. However, the expression of CIITA is considerably higher for patients and 
this up-regulation might be leading to the detectable difference. This highlights the 
need for studying expression in suitable cohorts or there may exist a substantial 
possibility for missing these discoveries.  
Due the extensive linkage in this locus, further molecular and mechanistic studies are 
needed to explain CIITAs role in the etiology of rheumatoid arthritis. 
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6 CONCLUDING REMARKS 
 
In this thesis work, we present advances for non-HLA genetic risk factors behind RA, a 
topic that has gained focus with the recent years development of whole genome 
techniques. These risk factors are very subtle and hard to distinguish and the effect of 
these variants is very likely also small. However, even small differences may have 
large consequences during the life span of a human being.  
A common theme for the studies of topic is increase of inhibitory regulation of disease 
associated variants. Effect of RA associated SNPs could lead to more restricted 
immune signaling with: 
DCIR full length variant is assumed to have an inhibitory function and a soluble form 
may counteract this. Less of this soluble form, which is seen in paper IV, may therefore 
lead to a higher inhibitory cell signaling. 
CIITA RA re-associated variant rs3087456, as we show in paper I, has a confirmed 
effect of both CIITA_pIII and CIITA_pIV with a lower expression for the RA risk 
allele. The association of CIITA with RA seems to be independent of the risk from 
HLA-DRB1 (paper II). 
PTPN22 620W variant is shown to be a gain of function mutation in many studies. In 
our paper V we complement this picture by showing that the expression of splice forms 
is different for RA patients and healthy controls with more of the full-length, putatively 
more active, splice form. This may increase the restriction for the T-cell receptor and 
also other cell surface receptors that may include PTPN22 for their signaling pathway. 
 
A combined orchestrated effect of all this risk variants together with other risk factors 
known for RA, perhaps in different time-points of disease development and at different 
cellular locations, may be what predispose certain individuals for rheumatoid arthritis, a 
complex disease which is heritable but with a low penetrance of genetic factors.  
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7 FUTURE PERSPECTIVES  
 
To continue to scrutinize the impact of CIITA on the risk for developing RA, studies in 
additional cohorts are warranted. If it is true that the effect is population restricted, 
further studies in theses populations could both reassure and reveal further risk variants. 
Also, this should be complemented with sequencing of the locus to find possible rare 
variants.  
As mentioned before, the CIITA locus has an extended LD around the promoter 
regions, which makes it almost impossible to separate the effect from a causal variant 
from other close variants. To find out if it is a specific effect of the rs3087456 SNP 
expression should be studied in a cell line with a point mutation at the -168 position.  
The difference in expression we have found for PTPN22 transcripts is from a pool of 
mononuclear cells from blood. It is possible, or even likely, that the effect is driven by a 
subset of these cells that will give a more pronounced effect. Therefore we should 
collect new samples from patients and controls and sort the cells in the major cell 
subset. Suitable cells would be CD4+ and CD8+ T-cells (separate naïve and 
active/memory cells), B-cells (naïve and active/memory), monocytes and dendritic 
cells. A longitudinal study with collection of samples starting from early RA patients 
could also answer whether this is a secondary pattern that increases with disease 
duration.  
With a collection of such samples, of separated and also possibly stimulated cells with 
interleukins and interferons, it would be possible to re-address the expression of all the 
targets in this thesis and also other to elucidate differences between patients and 
controls. Combining this with data from previously performed GWAS would lead to 
further powerful analyses. 
To cover as much data as possible for these samples, whole transcriptome sequencing 
would be a good alternative (cDNA sequencing) as a complement for targeting specific 
transcripts.  
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